In the SURMOUNT-1 obesity trial, participants the majority of whom were women lost a mean of up to roughly 20% of body weight at the highest dose over 72 weeks, according to the published results (PMID 35658024) and the registered protocol on ClinicalTrials.gov (NCT04184622)
doi: 10.1016/j.expneurol.2021.113762 232 DingWHuSWangPKangHPengRDongYet al
Currently sold under the brand names Alphagan and Brymont (Allergan, Inc., Irvine, CA, USA), brimonidine was patented in 1972 and became commercially available as a glaucoma treatment as an eyedrop formulation containing brimonidine tartrate
See also: Why patients fight to protect access to B12 shots as methylcobalamin Future of IV glutathione and B-12 shots still unsettled in California Crystal A
Disclosures: Alfred Barritt IV: Merck (Any division): Advisor, Madrigal: Consultant, Life Edit: Consultant, Boehringer Ingelheim: Consultant, Target-RWE: Consultant, Andrea Mospan: Nothing to Disclose, Breda Munoz: Nothing to Disclose, Rohit Loomba: Eli Lilly and Company: Consultant, Michael Fried: Nothing to Disclose, Brent Neuschwander-Tetri: Akero: Consultant, Aligos: Consultant, Arrowhead: Consultant, Corcept: Consultant, GSK: Consultant, Hepion: Consultant, HIstoIndex: Consultant, Madrigal: Consultant, Madrigal: Grant/Research Support, Merck: Consultant, Mirum: Consultant, Sagimet: Consultant, Senseion: Consultant, HepGene: Stock privately held company, HeptaBio: Stock privately held company, Philip Newsome: Novo Nordisk: Consultant, B Ingelheim: Consultant, Madrigal: Consultant, 89 Bio: Consultant, Sagimet: Consultant, Echosens: Speaking and Teaching, Eli Lilly: Speaking and Teaching, Zydus Therapeutics: Consultant, Abbott: Speaking and Teaching, Kenneth Cusi: Nothing to Disclose, Arun Sanyal: Genfit, Akarna, Tiziana, Durect, Inversago, Hemoshear, North: Stock - publicly traded company, Astra Zeneca ( 60K), Boston Pharmaceutical ( 50% OoF tiles were flagged as inadequate quality for reporting
